Active — Not RecruitingNot Applicable

A Study in Patients With Myasthenia Gravis in China

China1,199 participantsStarted 2024-09-26

Plain-language summary

This study is a multi-center, prospective cohort study designed to characterize current clinical practice, clinical and patient-reported outcomes (PROs), disease prognosis, treatment patterns and healthcare resource utilization for Chinese patients with myasthenia gravis (MG). This study will enroll patients with MG as diagnosed by physician. Approximately 1,200 MG patients are intended to be recruited from approximately 40 sites across majority of regions in China. The clinical and PROs included MGFA class, MGFA PIS, MG-ADL (Activities of Daily Living), QMG (Quantitative MG score), MG QOL-15R, EQ-5D etc. All MG patients enrolled will be followed up every 6 months until end of 2027.

Who can participate

Age range

0 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. Patients must have the following data to be enrolled in this study:
. MG patients or their legal guardians/representatives are able to sign the Informed Consent Form (ICF).

Exclusion criteria

. Patients aged ≥18 years with ocular myasthenia gravis (MGFA class I) lasting for more than 2 years;
. Patients who are currently participating in an interventional clinical trial cannot be enrolled in this study.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Clinical outcome

Timeframe: Every 6 months up to 3 years

Treatment method

Timeframe: Every 6 months up to 3 years

Patient-reported outcome

Timeframe: Every 6 months up to 3 years

Clinical outcome

Timeframe: Every 6 months up to 3 years

Clinical outcome

Timeframe: Every 6 months up to 3 years

Clinical outcome

Timeframe: Every 6 months up to 3 years

Clinical outcome

Timeframe: Every 6 months up to 3 years

Patient-reported outcome

Timeframe: Every 6 months up to 3 years

Trial details

NCT IDNCT06700616

SponsorAstraZeneca

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2027-12-30

View on ClinicalTrials.gov More Myasthenia Gravis trials

Plain-language summary

Who can participate

Age range

0 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. Patients must have the following data to be enrolled in this study:
. MG patients or their legal guardians/representatives are able to sign the Informed Consent Form (ICF).

Exclusion criteria

. Patients aged ≥18 years with ocular myasthenia gravis (MGFA class I) lasting for more than 2 years;
. Patients who are currently participating in an interventional clinical trial cannot be enrolled in this study.

What they're measuring

Clinical outcome

Timeframe: Every 6 months up to 3 years

Treatment method

Timeframe: Every 6 months up to 3 years

Patient-reported outcome

Timeframe: Every 6 months up to 3 years

Clinical outcome

Timeframe: Every 6 months up to 3 years

Clinical outcome

Timeframe: Every 6 months up to 3 years

Clinical outcome

Timeframe: Every 6 months up to 3 years

Clinical outcome

Timeframe: Every 6 months up to 3 years

Patient-reported outcome

Timeframe: Every 6 months up to 3 years